(0.09%) 5 474.02 points
(0.13%) 39 165 points
(0.39%) 17 786 points
(0.05%) $80.87
(-3.66%) $2.66
(-0.76%) $2 313.00
(0.23%) $28.94
(3.67%) $1 022.60
(0.28%) $0.936
(0.70%) $10.68
(0.44%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics...
Stats | |
---|---|
今日成交量 | 50 356 |
平均成交量 | 0 |
市值 | 52.26M |
EPS | $-0.0863 ( Q1 | 2024-05-08 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-28 | Desai Arjun Jj | Buy | 33 040 | Stock Options (Right to buy) |
2023-11-28 | Jacobovitz Shalom | Buy | 42 736 | Stock Options (Right to buy) |
2023-11-28 | Matlin David J | Buy | 56 024 | Stock Options (Right to buy) |
2023-11-28 | Kiernan Matthew | Buy | 28 730 | Stock Options (Right to buy) |
2023-11-28 | Mosca Alison | Buy | 43 814 | Stock Options (Right to buy) |
INSIDER POWER |
---|
99.46 |
Last 99 transactions |
Buy: 47 544 964 | Sell: 666 194 |
Clene Inc. 财务报表
Annual | 2023 |
营收: | $654 000 |
毛利润: | $-1.17M (-179.20 %) |
EPS: | $-0.470 |
FY | 2023 |
营收: | $654 000 |
毛利润: | $-1.17M (-179.20 %) |
EPS: | $-0.470 |
FY | 2022 |
营收: | $473 000 |
毛利润: | $447 000 (94.50 %) |
EPS: | $-0.230 |
FY | 2021 |
营收: | $723 000 |
毛利润: | $434 000 (60.03 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain\'s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson\'s Diseases. The company\'s products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。